Can you say "prevents" in Indian pharma promotional material?

Which instrument governs this

Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Section 3(d) read with the Schedule (and Section 3(a) for prevention of conception). Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clauses 1.2, 1.3 and 2.1. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.

UCPMP 2024 does not name this word. For a disease in the Schedule to the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, evidence does not lift the Section 3(d) bar. In our reading, rewording the claim does not escape it. The Code applies as well, whether or not the Act does. Under it, the claim must match the approved indication and be capable of substantiation.

What verification returned

Use of 'prevents' is restricted in India. Section 3(d) of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 is the first test for this word. It prohibits any advertisement suggesting a drug for the prevention of a disease, disorder or condition specified in the Act's Schedule or in rules under it. That bar is subject to the savings and exemptions in Sections 14 and 15. The Act covers doctor-directed material too, but Section 14(c) saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. Section 3(a) separately covers prevention of conception in women. In our reading, rewording such as 'reduces the risk of' still suggests prevention, so for a disease in the Schedule it does not escape Section 3(d). The Code's duties apply as well, whether or not the Act applies. The claim must be consistent with the marketing approval (Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.2). It must not mislead and must be capable of substantiation (Clause 1.3). It must be based on an up-to-date evaluation of all available evidence (Clause 2.1). Advertising to the public is also subject to the Consumer Protection Act, 2019. It is also subject to the Central Consumer Protection Authority's Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements, 2022. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 add a condition for Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). They say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team. Under Clause 1.2, prevention language must be consistent with the marketing approval, so in practice it needs an approved prophylaxis indication. For a disease in the Act's Schedule, that approval does not by itself lift the Section 3(d) bar.

How this was checked

Two independent AI models were asked the same question against the live web. They were Gemini 2.5 Pro with Google Search grounding, and OpenAI GPT-5 with web search. A third model then judged whether they agreed on the substance rather than the wording. Every source cited was fetched over HTTP to confirm it exists. A fetch confirms only that a source exists. It does not confirm that the source supports the statement. So on 6 October 2026 the citations on this page were re-checked. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules. They were corrected where they were wrong. Terms that did not reach agreement between the models are not published.

Sources checked

• UCPMP 2024, Department of Pharmaceuticals (PDF)
• UCPMP 2024, copy on the UCPMP portal of the Department of Pharmaceuticals (PDF)
• Drugs and Magic Remedies Act 1954, consolidated text on thc.nic.in (PDF)
• Drugs and Cosmetics Act 1940 and Rules 1945, CDSCO consolidated text (PDF)